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Tumours often become resistant to treatment but how this occurs is poorly understood. 
An analysis of how the protein Rb affects tumour growth and therapy response has 
implications for cancer treatment and drug development. See Letter p.XXX 
 
Seth M. Rubin & Julien Sage 
The development of cancer is invariably accompanied by cellular proteins performing 
unwanted activities or losing their function. Therapeutically targeting proteins that are 
more active than normal is conceptually straightforward — a drug needs to be found 
that, like a wrench thrown into a machine, specifically halts the malicious activity. By 
contrast, remedying the loss of a type of protein called a tumour suppressor, which 
normally opposes cancer growth, presents a conundrum. How can a protein be targeted 
by drugs if it is no longer present? One way to get around this problem and find new 
drug targets is to determine other consequences, such as molecular changes, that occur 
when a tumour suppressor is lost or does not function in a particular type of cancer. 
Writing in Nature, Walter et al.1 report their analysis of the role of the tumour suppressor 
protein retinoblastoma (Rb) using both an experimental system that allowed them to 
engineer the loss and re-activation of this protein in lung cancer in mice and human 
cancer cells grown in vitro[OK?].   
 
Since the discovery of the tumour-suppressor activity of Rb from studies of 
children with a type of eye cancer and the subsequent identification of Rb loss or 
inactivation as a characteristic of many human tumours, this protein has served as a 
model for studying tumour suppressors in cancer2. Rb can act as a key brake that halts 
cell-cycle progression and it promotes cellular differentiation into specific cell types. 
Many cancers block Rb function by increasing the activity of enzymes called cyclin-
dependent kinases (Cdks), which add phosphate groups to Rb to inactivate it3. There 
has been some success in the clinic with anticancer treatments that use inhibitor drugs 
that target Cdk4 and Cdk6 and prevent them from inactivating Rb. However, as would be 
expected, these inhibitors are not effective if Rb is not expressed, which might happen 
as a tumour evolves[OK? (or please revise to provide your preferred comment 
about Rb loss in tumours (for example, is Rb loss a common occurrence when 
treatment resistance occurs?)]4. A clear understanding of the consequences of Rb 
inactivation is lacking, which limits our ability to target tumours in which Rb is absent.   
 
Walter and colleagues studied the consequences of Rb loss in a mouse model of 
a common form of lung cancer called lung adenocarcinoma. The authors genetically 
engineered the animals so they could control whether and when Rb was made in lung-
cancer cells. This allowed them to make a key observation that the absence of Rb (a 
state termed an Rb knockout) promotes cancer development by causing an increase in 
both tumour growth and tumour spread to secondary sites in a process called 
metastasis. This provides some of the strongest in vivo evidence provided so far 
supporting a role for Rb loss not only in driving cancer initiation but also in promoting 
cancer progression.  
 
The authors observed that the molecular changes that lead to cancer progression 
and metastasis in this lung cancer model are strikingly different depending on whether 
Rb was present or absent. If Rb was missing, compared to the situation when Rb was 
present but inactivated by Cdks, the cancer cells had an increased propensity to change 
their cellular identity to a less-differentiated state, which allows the disease to progress 
more rapidly. Cellular dedifferentiation in the absence of Rb has also been observed in 
prostate cancer5. Although the precise mechanism controlling cellular plasticity in this 
scenario is unknown, it might involve the activation of factors involved in cellular 
reprogramming, such as the transcription-factor protein Sox2, which is normally inhibited 
by Rb6.  
 
Building on previous studies7,8 that investigated the consequences of Rb loss in 
mouse models of cancer, Walter and colleagues have deepened our understanding of 
Rb function by studying the effect of reinstating Rb expression in lung cancer months 
after the Rb-encoding gene was deleted by genetic engineering. This re-expression of 
Rb promoted the re-differentiation of undifferentiated cancer cells, thereby rendering the 
tumours less malignant. This observation is important because it suggests that 
strategies to re-activate Rb or to manipulate proteins that act downstream of Rb might 
have therapeutic benefits for the treatment of cancers that have lost Rb expression. 
 Another key observation made by Walter and colleagues is that tumours that lack 
Rb surprisingly do not upregulate the signalling pathway that contains the enzyme 
MAPK kinase, which is a pathway that is often activated in lung adenocarcinoma. This 
observation regarding the MAPK pathway had not been previously reported and is 
unexpected given that the upregulation of this pathway is a hallmark of this type of 
cancer. Their data strongly suggest that inactivation of Rb function is a major role of 
MAPK activation in lung cancer. MAPK signalling can cause Rb inactivation by several 
different mechanisms9. Walter et al. indicate that an increase of MAPK kinase signalling 
above normal in lung adenocarcinoma causes Rb inhibition because inactivation10 of the 
Cdk inhibitor protein called p27 causes the activation of Cdk2 — a Cdk family member 
that can3 phosphorylate and inactivate Rb.  
 
The success of inhibitors of Cdk4 and Cdk6 in the treatment of some tumours 
indicates that the manipulation of Rb activity can stop cancer progression. However, the 
observation of therapy resistance is motivating the search for other drugs that could re-
activate Rb and for the identification of additional targets that could be used in 
treatments for cancer cells that have lost Rb expression. Walter and colleagues’ success 
in identifying molecular and cellular consequences of Rb loss, such as cellular de-
differentiation and an absence of up-regulation of MAPK signalling, will help with these 
efforts.  
 
The authors’ observations regarding the interplay between MAPK and Cdk2 
implicates Cdk2 as a potential drug target in lung cancers that have Rb but are 
nevertheless resistant to inhibitors of Cdk4 and Cdk6. In this context the combined 
inhibition of MAPK and Cdk2, or the combined inhibition of Cdk4, Cdk6 and Cdk2 might 
potently stop the growth of lung tumours by ensuring that Rb is not deactivated by 
phosphorylation (Fig. 1). However, more work will be needed to identify additional 
potential drug targets. Efforts should also be made to determine the sensitivity of a 
person’s cancer to inhibitors of Cdk4 and Cdk6 or Cdk2, including assessing a person’s 
genetic profile and monitoring alterations termed epigenetic changes that are 
modifications of DNA or DNA-binding proteins. It would be useful to try to identify 
targetable proteins or pathways that inhibit the cellular dedifferentiation that occurs upon 
Rb loss.  
 
It will be essential to understand to what extent the principles of lung cancer 
development and progression are applicable to other types of cancer. The experimental 
system used by Walter et al. could help to address this challenge because their results 
might be relevant for understanding the effect of loss of tumour suppressor proteins in 
diverse contexts[OK?]. Studies of Rb have long provided a useful model system to 
investigate fundamental mechanisms of tumour suppression. Now they might also offer 
a way forward to uncover new anti-cancer strategies. 
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Figure 1 | Rb protein in cancer cells. a, Rb is a type of protein known as tumour 
suppressor that can help to block cancer when it is active. A common feature of lung 
cancer is Rb inactivation by the addition of phosphate groups (P) to the protein. This can 
occur through a pathway that requires the action of the enzyme MAPK and the enzymes 
Cdk4 and Cdk6 or the enzyme Cdk2. b, Drugs currently in use in the clinic for lung 
cancer (green) block the action of MAPK or Cdk4 and Cdk6. Walter et al.1 studied a 
mouse model of lung cancer and report that Cdk2 has a major role in the inactivation of 
Rb. Therefore the development of drugs that target this protein might have promise as a 
new way to treat lung cancer. c, Rb expression is often lost in lung cancer. Walter and 
colleagues studied the consequence of Rb loss that they engineered in mouse models of 
lung cancer. This resulted in a loss of cellular differentiation and an increase in the 
spread of cancer cells to other sites in the body through a process called metastasis. 
Proteins implicated in such changes, like the proteins Sox2 or HMGA2, might offer 
targets to be investigated for future drug development.  
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